Please try another search
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer’s disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Name | Age | Since | Title |
---|---|---|---|
Kunio Iwatani | 81 | 2015 | Independent External Director |
Masayoshi Matsumura | 79 | 2002 | Chairman |
Hiroshi Akitomo | 62 | 2005 | Manager of Development Department and Director |
Keiko Yamasaki | 73 | 2002 | Manager of Quality Control Department and Director |
Ken Fujioka | - | 2020 | GM of Business Administration Department & Director |
Yonehiro Matsumura | 53 | 2013 | President, CEO & Representative Director |
Hidetoshi Hamamoto | 54 | 2011 | Manager of Research Department and Director |
Hiroshi Danno | 55 | 2007 | External Auditor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review